(NASDAQ: GNLX) Genelux's forecast annual revenue growth rate of 3,129.46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Genelux's revenue in 2025 is $8,000.On average, 1 Wall Street analysts forecast GNLX's revenue for 2026 to be $1,356,488,403, with the lowest GNLX revenue forecast at $1,356,488,403, and the highest GNLX revenue forecast at $1,356,488,403. On average, 1 Wall Street analysts forecast GNLX's revenue for 2027 to be $5,335,982,443, with the lowest GNLX revenue forecast at $5,335,982,443, and the highest GNLX revenue forecast at $5,335,982,443.
In 2028, GNLX is forecast to generate $9,325,857,772 in revenue, with the lowest revenue forecast at $9,325,857,772 and the highest revenue forecast at $9,325,857,772.